These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 18199038)

  • 1. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline.
    Anthony KB; Fishman NO; Linkin DR; Gasink LB; Edelstein PH; Lautenbach E
    Clin Infect Dis; 2008 Feb; 46(4):567-70. PubMed ID: 18199038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs.
    Mezzatesta ML; Caio C; Gona F; Cormaci R; Salerno I; Zingali T; Denaro C; Gennaro M; Quattrone C; Stefani S
    Int J Antimicrob Agents; 2014 Aug; 44(2):112-6. PubMed ID: 25059444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.
    Bertrand X; Dowzicky MJ
    Clin Ther; 2012 Jan; 34(1):124-37. PubMed ID: 22154196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ; Park CH
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
    Bouchillon SK; Iredell JR; Barkham T; Lee K; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of tigecycline resistance in Klebsiella pneumoniae in a single patient.
    Al-Qadheeb NS; Althawadi S; Alkhalaf A; Hosaini S; Alrajhi AA
    Ann Saudi Med; 2010; 30(5):404-7. PubMed ID: 20697161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug-resistant Gram-negative infections: what are the treatment options?
    Giamarellou H; Poulakou G
    Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of multidrug-resistant Gram-negative infections in children.
    Hsu AJ; Tamma PD
    Clin Infect Dis; 2014 May; 58(10):1439-48. PubMed ID: 24501388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum β-Lactamases and Beyond.
    Boyle DP; Zembower TR
    Urol Clin North Am; 2015 Nov; 42(4):493-505. PubMed ID: 26475946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens.
    Poulakou G; Kontopidou FV; Paramythiotou E; Kompoti M; Katsiari M; Mainas E; Nicolaou C; Yphantis D; Antoniadou A; Trikka-Graphakos E; Roussou Z; Clouva P; Maguina N; Kanellakopoulou K; Armaganidis A; Giamarellou H
    J Infect; 2009 Apr; 58(4):273-84. PubMed ID: 19344841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review.
    Brust K; Evans A; Plemmons R
    J Antimicrob Chemother; 2014 Oct; 69(10):2606-10. PubMed ID: 24879669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of tigecycline and comparators against gram-negative bacteria isolated from a tertiary hospital in Alexandria, Egypt.
    Mohamed NM; Youssef AA
    Microb Drug Resist; 2011 Dec; 17(4):489-95. PubMed ID: 21875338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activity of tigecycline and nine other antibiotics against gram-negative bacterial isolates, including ESBL-producing strains.
    Jamal WY; Al Hashem G; Khodakhast F; Rotimi VO
    J Chemother; 2009 Jun; 21(3):261-6. PubMed ID: 19567345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity among gram-positive and gram-negative organisms collected from the Asia-Pacific region as part of the Tigecycline Evaluation and Surveillance Trial: Comparison of 2015 results with previous years.
    Yang Q; Xu YC; Kiratisin P; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2017 Dec; 89(4):314-323. PubMed ID: 28951056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG; Karlowsky JA; Rubinstein E; Hoban DJ
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives.
    Rizek C; Ferraz JR; van der Heijden IM; Giudice M; Mostachio AK; Paez J; Carrilho C; Levin AS; Costa SF
    J Infect Chemother; 2015 Feb; 21(2):114-7. PubMed ID: 25456893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.